Webinar Archives - Touchlight https://touchlight.com/tag/webinar/ DNA is our DNA™ Tue, 21 Apr 2026 15:59:04 +0000 en-US hourly 1 https://touchlight.com/wp-content/uploads/2025/06/cropped-Favicon-32x32.png Webinar Archives - Touchlight https://touchlight.com/tag/webinar/ 32 32 The Great DNA Debate: Plasmid vs. Cell-Free DNA https://touchlight.com/the-great-dna-debate-plasmid-vs-cell-free-dna-2/ Tue, 10 Mar 2026 16:32:06 +0000 https://touchlight.com/?p=5576 The post The Great DNA Debate: Plasmid vs. Cell-Free DNA appeared first on Touchlight.

]]>
Webinar
5 mins
AAV
,
DNA Vaccines
,
Gene editing
,
Lentivirus
,
mRNA
,
Non-viral gene therapy

The Great DNA Debate: Plasmid vs. Cell-Free DNA

Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time, cell‑free DNA has already reached clinical use, where it is increasingly adopted to treat patients and now operates alongside plasmid DNA within today’s manufacturing landscape. How can companies optimize and select the right DNA technology to meet evolving demands for scale, consistency, speed, and cost of goods?

Download the webinar to watch as two leading DNA experts have a candid debate with real-world data exploring where plasmid DNA continues to excel, where cell-free DNA is uniquely positioned, and how both platforms will shape the future of the cell and gene therapy landscape.

Access the webinar here:

The post The Great DNA Debate: Plasmid vs. Cell-Free DNA appeared first on Touchlight.

]]> From Plasmids to Cell-free DNA using Megabulb DNA: How Touchlight and ElevateBio are Enabling Safer and More Effective Cell and Gene Therapies https://touchlight.com/from-plasmids-to-cell-free-dna-using-megabulb-dna/ Thu, 23 Oct 2025 20:40:01 +0000 https://touchlight.com/?p=5065 The post From Plasmids to Cell-free DNA using Megabulb DNA: How Touchlight and ElevateBio are Enabling Safer and More Effective Cell and Gene Therapies appeared first on Touchlight.

]]>
Webinar
5 mins
Gene editing

From Plasmids to Cell-free DNA using Megabulb DNA: How Touchlight and ElevateBio are Enabling Safer and More Effective Cell and Gene Therapies

In this session, Elena Stoyanova, PhD (Touchlight) introduces mbDNA™ (Megabulb DNA), a novel single-stranded circular DNA template featuring a customizable stem region and fully user-defined sequence. Chesney Michels, PhD (ElevateBio) highlights how mbDNA™ was applied in combination with Life Edit’s™ LEG14 nuclease, a proprietary RNA-guided nuclease, to enable efficient, targeted genome editing. Together, these technologies were used to knock out the endogenous TCR and insert an exogenous TCR targeting the NYESO-1 antigen. HDR-mediated knock-in with two distinct circular donor templates—MegabulbDNA™ (circular, single-stranded DNA) and Plasmid (next generation circular double stranded)—facilitated stable genome integration, with mbDNA™ yielding a 2-fold increase in anti-NYESO-1 TCR T cells.

Discover how this nuclease-driven, non-viral approach offers a scalable, versatile, and precise solution for next-generation T cell therapies.

Download the webinar to learn:

  • The limitations of viral transduction and explore how non-viral methods such as CRISPR-based genome editing are addressing challenges in cost, safety, and scalability for T cell engineering
  • mbDNA™, a novel circular single-stranded DNA template, and how its customizable design enables precise and efficient genome editing in combination with proprietary nucleases
  • Gain insights into a real-world application of mbDNA™ and LEG14 nuclease for targeted TCR knock-in, including comparative performance data with Plasmid (next generation circular double stranded) and the implications for next-generation T cell therapies

Access the webinar here:

The post From Plasmids to Cell-free DNA using Megabulb DNA: How Touchlight and ElevateBio are Enabling Safer and More Effective Cell and Gene Therapies appeared first on Touchlight.

]]> Technology Talk – An introduction to dbDNA™ and mbDNA™ https://touchlight.com/technology-talk-an-introduction-to-dbdna-and-mbdna/ Tue, 08 Jul 2025 23:05:30 +0000 https://touchlight.com/?p=3830 The post Technology Talk – An introduction to dbDNA™ and mbDNA™ appeared first on Touchlight.

]]>
Webinar
4 mins
Gene editing

Technology Talk – An introduction to dbDNA™ and mbDNA™

In this webinar, Touchlight’s Elena Stoyanova, PhD introduces the company’s innovative DNA manufacturing technologies, focusing on their proprietary dbDNA™ (Doggybone DNA) and the newly developed mbDNA™ (MegaBulb DNA ). She explains how dbDNA, a minimal, enzymatically amplified linear DNA vector, offers advantages over traditional plasmid DNA, including higher purity, faster production, and improved safety. The session also highlights mbDNA, a novel circular single-stranded DNA template designed to overcome limitations in gene editing by enhancing stability, manufacturability, and knock-in efficiency for HDR applications.

Download the webinar to learn:

  • How dbDNA and mbDNA technologies address key challenges in gene therapy and gene editing.
  • Understand the structural and functional advantages of enzymatically produced DNA over traditional plasmid and viral vectors.
  •  Insights into scalable, non-viral DNA manufacturing solutions for next-generation therapeutics.

Access the webinar here:

The post Technology Talk – An introduction to dbDNA™ and mbDNA™ appeared first on Touchlight.

]]> Non-viral Cell Engineering with Stanford University, Touchlight, and MaxCyte: Advantages and Applications https://touchlight.com/non-viral-cell-engineering-with-stanford-university-touchlight-and-maxcyte-advantages-and-applications/ Mon, 11 Dec 2023 10:09:47 +0000 https://touchlight.upthere.studio/?p=1485 The post Non-viral Cell Engineering with Stanford University, Touchlight, and MaxCyte: Advantages and Applications appeared first on Touchlight.

]]>
Webinar
5 mins
Non-viral gene therapy

Non-viral Cell Engineering with Stanford University, Touchlight, and MaxCyte: Advantages and Applications

Elena Stoyanova, Hyatt Balke-Want, Marianna Romito, Debra Barberini
MaxCyte-ondemand-webinar

In this virtual seminar, cell engineering scientists from Stanford University, Touchlight Genetics, and MaxCyte share promising advances in non-viral gene therapy. Join these experts from across the globe and learn about the latest innovations in gene delivery platforms and single-stranded CRISPR HDR donor technologies.

Key case studies will presented by Dr. Hyatt Want at Stanford University (Crystal Mackall & Steve Feldman Labs), Dr. Elena Stoyanova at Touchlight Genetics, and Dr. Marianna Romito at MaxCyte.

Each presenter will share data on how to increase engineering efficiency in primary and stem cells, all while maintaining high cell viability and recovery for applications in gene editing and autologous/allogeneic cell therapy.

Access the article here:

The post Non-viral Cell Engineering with Stanford University, Touchlight, and MaxCyte: Advantages and Applications appeared first on Touchlight.

]]>